Pfizer Discontinues Heart Disease Research
Posted on: Sunday, 3 December 2006, 15:00 CST
The New York-based pharmaceutical company Pfizer says it has discontinued research on its heart disease drug, torcetrapib.
The company revealed its plans to cease research on torcetrapib Saturday, citing concerns that the drug may have been linked to heart problems and deaths during preliminary research, The New York Times reported.
The drug had been heralded by the company as a breakthrough for its reported ability to raise levels of good cholesterol and to reduce bad cholesterol when combined with various other drugs.
Pfizer's decision to discontinue the related research could prove devastating for the world's largest drug company, as it marks yet another unsuccessful production endeavor and the loss of billions of dollars in sales for the company.
The Times said prior to Saturday's announcement, Pfizer has faced major difficulties in the creation of new drugs and is eyeing a major financial loss when its Lipitor drug loses patent protection in 2010.
Source: United Press International
Related Articles
- Drug Maker Pfizer Buys Out Rival Wyeth
- Research and Markets: In February 2008, a Dutch Court Ruled Against Us Drug-Maker Pfizer in a Court Case Regarding the Patent on Atorvastatin
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- South Texas Accelerated Research Therapeutics Gains Highly Respected Cancer Drug Researcher Michael Wick, Ph.D.
- Understanding the Issues Relating to Chirality in Drug Research
- Drug-Research Firm to Open in Old Mill
- Top Drug Researcher Lands at U: Her $7.8 Million NIH Grant Will Follow Her
- AaiPharma Tries to Regain Its Footing in the Contract Drug Research Industry
- Drug Researcher MDS Adds Beds in Lincoln
- Drug Researchers Leak Secrets to Wall St.
 |
 |
User Comments (0)
RSS Feeds